The Use of Agonistic Anti-CD40 Therapy in Treatments for Cancer

REFERENCES

• Yellin MJ, Functional interactions of T cells with endothelial cells: the role of CD40L–CD40-mediated signals. J Exp Med. 1995;182(6):1857–1864.
   PubMed Web of Science ®Google Scholar
• Chiodoni C, Triggering CD40 on endothelial cells contributes to tumor growth. J Exp Med. 2006;203(11):2441–2450.
   PubMed Web of Science ®Google Scholar
• Hamzah J, Vascular targeting of anti-CD40 antibodies and IL-2 into autochthonous tumors enhances immunotherapy in mice. J Clin Invest. 2008;118(5):1691–1699.
   Google Scholar
• Banchereau J, The CD40 antigen and its ligand. Annu Rev Immunol. 1994;12:881–922.
   PubMed Web of Science ®Google Scholar
• Law CL, Grewal IS. Therapeutic interventions targeting CD40L (CD154) and CD40: the opportunities and challenges. Adv Exp Med Biol. 2009;647:8–36.
   PubMed Web of Science ®Google Scholar
• Costello RT, Gastaut JA, Olive D. Tumor escape from immune surveillance. Arch Immunol Ther Exp (Warsz). 1999;47(2):83–88.
   PubMedGoogle Scholar
• Restifo NP, Molecular mechanisms used by tumors to escape immune recognition: immunogenetherapy and the cell biology of major histocompatibility complex class I. J Immunother Emphasis Tumor Immunol. 1993;14(3):182–190.
   Google Scholar
• Gajewski TF, Immune resistance orchestrated by the tumor microenvironment. Immunol Rev. 2006;213:. 131–145.
   PubMed Web of Science ®Google Scholar
• Jackaman C, IL-2 intratumoral immunotherapy enhances CD8+ T cells that mediate destruction of tumor cells and tumor-associated vasculature: a novel mechanism for IL-2. J Immunol. 2003;171(10):5051–5063.
   PubMed Web of Science ®Google Scholar
• Jackaman C, Deliberately provoking local inflammation drives tumors to become their own protective vaccine site. Int Immunol. 2008;20(11):1467–1479.
   Google Scholar
• Melief CJ. Cancer immunotherapy by dendritic cells. Immunity. 2008;29(3):372–383.
   PubMed Web of Science ®Google Scholar
• Burgdorf S, Kurts C. Endocytosis mechanisms and the cell biology of antigen presentation. Curr Opin Immunol. 2008;20(1):89–95.
   PubMed Web of Science ®Google Scholar
• Kurts C, Robinson BW, Knolle PA. Cross-priming in health and disease. Nat Rev Immunol. 2010;10(6):403–414.
   PubMed Web of Science ®Google Scholar
• McDonnell AM, Robinson BW, Currie AJ. Tumor antigen cross-presentation and the dendritic cell: where it all begins? Clin Dev Immunol. 2010; Article ID 539519, 9 pages, 2010.
   Google Scholar
• Ghiringhelli F, Tumor cells convert immature myeloid dendritic cells into TGF-beta-secreting cells inducing CD4+CD25+ regulatory T cell proliferation. J Exp Med. 2005;202(7):919–929.
   PubMed Web of Science ®Google Scholar
• Gabrilovich D. Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nat Rev Immunol. 2004;4(12):941–952.
   PubMed Web of Science ®Google Scholar
• Kurts C, CD8 T cell ignorance or tolerance to islet antigens depends on antigen dose. Proc Natl Acad Sci U S A. 1999;96(22):12703–12707.
   PubMed Web of Science ®Google Scholar
• Marzo AL, Tumor-specific CD4+ T cells have a major “post-licensing” role in CTL mediated anti-tumor immunity. J Immunol. 2000;165(11):6047–6055.
   PubMed Web of Science ®Google Scholar
• Sparso T, The GCKR rs780094 polymorphism is associated with elevated fasting serum triacylglycerol, reduced fasting and OGTT-related insulinaemia, and reduced risk of type 2 diabetes. Diabetologia. 2008;51(1):70–75.
   PubMed Web of Science ®Google Scholar
• Burgdorf C, Schunkert H, Kurowski V. Is concomitant coronary artery disease an exclusion criterion for transient left ventricular apical ballooning? Int J Cardiol. 2008;125(1):e8–e9.
   Google Scholar
• Grohmann U, CD40 ligation ablates the tolerogenic potential of lymphoid dendritic cells. J Immunol. 2001;166(1):277–283.
   Google Scholar
• Hunter TB, An agonist antibody specific for CD40 induces dendritic cell maturation and promotes autologous anti-tumour T-cell responses in an in vitro mixed autologous tumour cell/lymph node cell model. Scand J Immunol. 2007;65(5):479–486.
   Google Scholar
• Ridge JP, Di Rosa F, Matzinger P. A conditioned dendritic cell can be a temporal bridge between a CD4+ T-helper and a T-killer cell. Nature. 1998;393(6684):474–478.
   PubMed Web of Science ®Google Scholar
• Cella M, Ligation of CD40 on dendritic cells triggers production of high levels of interleukin-12 and enhances T cell stimulatory capacity: T-T help via APC activation. J Exp Med. 1996;184(2):747–752.
   PubMed Web of Science ®Google Scholar
• Toes RE, CD40–CD40 ligand interactions and their role in cytotoxic T lymphocyte priming and anti-tumor immunity. Semin Immunol. 1998;10(6):443–448.
   PubMed Web of Science ®Google Scholar
• Schoenberger SP, T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions. Nature. 1998;393(6684):480–483.
   PubMed Web of Science ®Google Scholar
• French RR, CD40 antibody evokes a cytotoxic T-cell response that eradicates lymphoma and bypasses T-cell help. Nat Med. 1999;5(5):548–553.
   PubMed Web of Science ®Google Scholar
• Jackaman C, Nelson DJ. Intratumoral interleukin-2/agonist CD40 antibody drives CD4(+)-independent resolution of treated-tumors and CD4(+)-dependent systemic and memory responses. Cancer Immunol Immunother. 2012;61:549–560.
   PubMed Web of Science ®Google Scholar
• Bourgeois C, CD8 lethargy in the absence of CD4 help. Eur J Immunol. 2002;32(8):2199–2207.
   Google Scholar
• Nagy JA, Why are tumour blood vessels abnormal and why is it important to know? Br J Cancer. 2009;100(6):865–869.
   PubMed Web of Science ®Google Scholar
• van Mierlo GJ, Activation of dendritic cells that cross-present tumor-derived antigen licenses CD8+ CTL to cause tumor eradication. J Immunol. 2004;173(11):6753–6759.
   Google Scholar
• Todryk SM, CD40 ligation for immunotherapy of solid tumours. J Immunol Methods. 2001;248(1–2):139–147.
   PubMed Web of Science ®Google Scholar
• Marzo AL, Tumor antigens are constitutively presented in the draining lymph nodes. J Immunol. 1999;162(10):5838–5845.
   PubMed Web of Science ®Google Scholar
• Stumbles PA, Cutting edge: tumor-specific CTL are constitutively cross-armed in draining lymph nodes and transiently disseminate to mediate tumor regression following systemic CD40 activation. J Immunol. 2004;173(10):5923–5928.
   Google Scholar
• den Haan JM, Bevan MJ. Constitutive versus activation-dependent cross-presentation of immune complexes by CD8(+) and CD8(-) dendritic cells in vivo. J Exp Med. 2002;196(6):817–827.
   Google Scholar
• Moron G, CD8alpha- CD11b+ dendritic cells present exogenous virus-like particles to CD8+ T cells and subsequently express CD8alpha and CD205 molecules. J Exp Med. 2002;195(10):1233–1245.
   PubMedGoogle Scholar
• Pooley JL, Heath WR, Shortman K. Cutting edge: intravenous soluble antigen is presented to CD4 T cells by CD8- dendritic cells, but cross-presented to CD8 T cells by CD8+ dendritic cells. J Immunol. 2001;166(9):5327–5330.
   PubMed Web of Science ®Google Scholar
• Ruter J, Immune modulation with weekly dosing of an agonist CD40 antibody in a phase I study of patients with advanced solid tumors. Cancer Biol Ther. 2010;10(10):983–993.
   PubMed Web of Science ®Google Scholar
• Backer R, CD8- dendritic cells preferentially cross-present Saccharomyces cerevisiae antigens. Eur J Immunol. 2008;38(2):370–380.
   Google Scholar
• Ballesteros-Tato A, Temporal changes in dendritic cell subsets, cross-priming and costimulation via CD70 control CD8(+) T cell responses to influenza. Nat Immunol. 2010;11(3):216–224.
   PubMed Web of Science ®Google Scholar
• Bedoui S, Cross-presentation of viral and self antigens by skin-derived CD103+ dendritic cells. Nat Immunol. 2009;10(5):488–495.
   PubMed Web of Science ®Google Scholar
• del Rio ML, CD103- and CD103+ bronchial lymph node dendritic cells are specialized in presenting and cross-presenting innocuous antigen to CD4+ and CD8+ T cells. J Immunol. 2007;178(11): p. 6861–6866.
   Google Scholar
• Gerner MY, Casey KA, Mescher MF. Defective MHC class II presentation by dendritic cells limits CD4 T cell help for antitumor CD8 T cell responses. J Immunol. 2008;181(1):155–164.
   Google Scholar
• McDonnell AM, CD8alpha+ DC are not the sole subset cross-presenting cell-associated tumor antigens from a solid tumor. Eur J Immunol. 2010;40(6):1617–1627.
   Google Scholar
• Lee BO, CD40, but not CD154, expression on B cells is necessary for optimal primary B cell responses. J Immunol. 2003;171(11):5707–5717.
   Web of Science ®Google Scholar
• Buhmann R, CD40-activated B-cell chronic lymphocytic leukemia cells for tumor immunotherapy: stimulation of allogeneic versus autologous T cells generates different types of effector cells. Blood. 1999;93(6):1992–2002.
   PubMed Web of Science ®Google Scholar
• Lapointe R, CD40-stimulated B lymphocytes pulsed with tumor antigens are effective antigen-presenting cells that can generate specific T cells. Cancer Res. 2003;63(11):2836–2843.
   PubMed Web of Science ®Google Scholar
• Coughlin CM, RNA-transfected CD40-activated B cells induce functional T-cell responses against viral and tumor antigen targets: implications for pediatric immunotherapy. Blood. 2004;103(6):2046–2054.
   PubMed Web of Science ®Google Scholar
• Kim SK, Induction of myeloma-specific cytotoxic T lymphocytes ex vivo by CD40-activated B cells loaded with myeloma tumor antigens. Ann Hematol. 2009;88(11):1113–1123.
   Google Scholar
• Gordon J, Anti-tumor immunity in B-lymphocyte-deprived mice, III: immunity to primary Moloney sarcoma virus-induced tumors. Int J Cancer. 1982;29(3):351–357.
   Google Scholar
• Schultz KR, The role of B cells for in vivo T cell responses to a Friend virus-induced leukemia. Science. 1990;249(4971):921–923.
   Google Scholar
• DiLillo DJ, K. Yanaba, Tedder TF B cells are required for optimal CD4+ and CD8+ T cell tumor immunity: therapeutic B cell depletion enhances B16 melanoma growth in mice. J Immunol. 2010;184(7):4006–4016.
   PubMed Web of Science ®Google Scholar
• Qin Z, B cells inhibit induction of T cell-dependent tumor immunity. Nat Med. 1998;4(5):627–630.
   PubMed Web of Science ®Google Scholar
• Jackaman C, CD40-activated B cells contribute to mesothelioma tumor regression. Immunol Cell Biol. 2011;89(2):255–267.
   PubMed Web of Science ®Google Scholar
• Carpenter EL, Activation of human B cells by the agonist CD40 antibody CP-870,893 and augmentation with simultaneous Toll-like receptor 9 stimulation. J Transl Med. 2009;7:93.
   PubMed Web of Science ®Google Scholar
• Perricone MA, Enhanced efficacy of melanoma vaccines in the absence of B lymphocytes. J Immunother. 2004;27(4):273–281.
   Google Scholar
• Clatworthy MR, B-cell-depleting induction therapy and acute cellular rejection. N Engl J Med. 2009;360(25):2683–2685.
   PubMed Web of Science ®Google Scholar
• Kondo E, Efficient generation of antigen-specific cytotoxic T cells using retrovirally transduced CD40-activated B cells. J Immunol. 2002;169(4):2164–2171.
   Google Scholar
• Schultze JL, CD40-activated human B cells: an alternative source of highly efficient antigen presenting cells to generate autologous antigen-specific T cells for adoptive immunotherapy. J Clin Invest. 1997;100(11):2757–2765.
   Google Scholar
• von Bergwelt-Baildon MS, Human primary and memory cytotoxic T lymphocyte responses are efficiently induced by means of CD40-activated B cells as antigen-presenting cells: potential for clinical application. Blood. 2002;99(9):3319–3325.
   Google Scholar
• von Bergwelt-Baildon M, CD40-activated B cells express full lymph node homing triad and induce T-cell chemotaxis: potential as cellular adjuvants. Blood. 2006;107(7):2786–2789.
   Google Scholar
• Murugaiyan G, Martin S, Saha B. CD40-induced countercurrent conduits for tumor escape or elimination? Trends Immunol. 2007;28(11):467–473.
   Google Scholar
• Garbi N, CpG motifs as proinflammatory factors render autochthonous tumors permissive for infiltration and destruction. J Immunol. 2004;172(10):5861–5869.
   PubMed Web of Science ®Google Scholar
• Tong AW, CD40 ligand-induced apoptosis is Fas-independent in human multiple myeloma cells. Leuk Lymphoma. 2000;36(5–6):543–558.
   PubMed Web of Science ®Google Scholar
• Restifo NP, Identification of human cancers deficient in antigen processing. J Exp Med. 1993;177(2):265–272.
   Google Scholar
• Kikuchi T, Crystal RG, Anti-tumor immunity induced by in vivo adenovirus vector-mediated expression of CD40 ligand in tumor cells. Hum Gene Ther. 1999;10(8):1375–1387.
   Google Scholar
• Kikuchi T, Tumor regression induced by intratumor administration of adenovirus vector expressing CD40 ligand and naive dendritic cells. Cancer Res. 2000;60(22):6391–6395.
   PubMed Web of Science ®Google Scholar
• Friedlander PL, Efficacy of CD40 ligand gene therapy in malignant mesothelioma. Am J Respir Cell Mol Biol. 2003;29(3 Pt 1):321–330.
   Google Scholar
• Andersen NS, Soluble CD40 ligand induces selective proliferation of lymphoma cells in primary mantle cell lymphoma cell cultures. Blood. 2000;96(6):2219–2225.
   PubMed Web of Science ®Google Scholar
• Challa A, Population depletion activates autonomous CD154-dependent survival in biopsylike Burkitt lymphoma cells. Blood. 2002;99(9):3411–3418.
   Google Scholar
• Buhtoiarov IN, CD40 ligation activates murine macrophages via an IFN-gamma-dependent mechanism resulting in tumor cell destruction in vitro. J Immunol. 2005;174(10):6013–6022.
   Google Scholar
• Lum HD, In vivo CD40 ligation can induce T-cell-independent antitumor effects that involve macrophages. J Leukoc Biol. 2006;79(6):1181–1192.
   PubMed Web of Science ®Google Scholar
• Buhtoiarov IN, Synergistic activation of macrophages via CD40 and TLR9 results in T cell independent antitumor effects. J Immunol. 2006;176(1):309–318.
   Google Scholar
• Lum HD, Tumoristatic effects of anti-CD40 mAb-activated macrophages involve nitric oxide and tumour necrosis factor-alpha. Immunology. 2006;118(2):261–270.
   Google Scholar
• Turner JG, Anti-CD40 antibody induces antitumor and antimetastatic effects: the role of NK cells. J Immunol. 2001;166(1):89–94.
   PubMed Web of Science ®Google Scholar
• Zhang M, Interleukin-15 combined with an anti-CD40 antibody provides enhanced therapeutic efficacy for murine models of colon cancer. Proc Natl Acad Sci U S A. 2009;106(18):7513–7518.
   PubMed Web of Science ®Google Scholar
• Jackaman C, IL-2/CD40-driven NK cells install and maintain potency in the anti-mesothelioma effector/memory phase. Int Immunol. 2012;24(6):357–68.
   PubMed Web of Science ®Google Scholar
• Fransen MF, Local activation of CD8 T cells and systemic tumor eradication without toxicity via slow release and local delivery of agonistic CD40 antibody. Clin Cancer Res. 2011;17(8):2270–2280.
   PubMed Web of Science ®Google Scholar
• Gladue RP, The CD40 agonist antibody CP-870,893 enhances dendritic cell and B-cell activity and promotes anti-tumor efficacy in SCID-hu mice. Cancer Immunol Immunother. 2011;60(7):1009–1017.
   PubMed Web of Science ®Google Scholar
• Vonderheide RH, Clinical activity and immune modulation in cancer patients treated with CP-870,893, a novel CD40 agonist monoclonal antibody. J Clin Oncol. 2007;25(7):876–883.
   PubMed Web of Science ®Google Scholar
• Broomfield S, Partial, but not complete, tumor-debulking surgery promotes protective antitumor memory when combined with chemotherapy and adjuvant immunotherapy. Cancer Res. 2005;65(17):7580–7584.
   Google Scholar
• Broomfield SA, Locally administered TLR7 agonists drive systemic antitumor immune responses that are enhanced by anti-CD40 immunotherapy. J Immunol. 2009;182(9):5217–5224.
   PubMed Web of Science ®Google Scholar
• Nowak AK, Robinson BW, Lake RA. Synergy between chemotherapy and immunotherapy in the treatment of established murine solid tumors. Cancer Res. 2003;63(15):4490–4496.
   PubMed Web of Science ®Google Scholar
• Houtenbos I, The novel bispecific diabody alphaCD40/alphaCD28 strengthens leukaemic dendritic cell-induced T-cell reactivity. Br J Haematol. 2008;142(2):273–283.
   Google Scholar
• Kwong B, Liu H, Irvine DJ. Induction of potent anti-tumor responses while eliminating systemic side effects via liposome-anchored combinatorial immunotherapy. Biomaterials. 2011;32(22):5134–5147.
   PubMed Web of Science ®Google Scholar
• Murphy WJ, Synergistic anti-tumor responses after administration of agonistic antibodies to CD40 and IL-2: coordination of dendritic and CD8+ cell responses. J Immunol. 2003;170(5):2727–2733.
   PubMed Web of Science ®Google Scholar
• Berner V, IFN-gamma mediates CD4+ T-cell loss and impairs secondary antitumor responses after successful initial immunotherapy. Nat Med. 2007;13(3):354–360.
   PubMed Web of Science ®Google Scholar
• Alderson KL, Regulatory and conventional CD4+ T cells show differential effects correlating with PD-1 and B7-H1 expression after immunotherapy. J Immunol. 2008;180(5):2981–2988.
   Google Scholar
• Weiss JM, Successful immunotherapy with IL-2/anti-CD40 induces the chemokine-mediated mitigation of an immunosuppressive tumor microenvironment. Proc Natl Acad Sci U S A. 2009;106(46):19455–19460.
   PubMed Web of Science ®Google Scholar
• Currie AJ, Targeting the effector site with IFN-alphabeta-inducing TLR ligands reactivates tumor-resident CD8 T cell responses to eradicate established solid tumors. J Immunol. 2008;180(3):1535–1544.
   Google Scholar
• Ahonen CL, Enhanced efficacy and reduced toxicity of multifactorial adjuvants compared with unitary adjuvants as cancer vaccines. Blood. 2008;111(6):3116–3125.
   PubMed Web of Science ®Google Scholar
• Ahonen CL, Combined TLR and CD40 triggering induces potent CD8+ T cell expansion with variable dependence on type I IFN. J Exp Med. 2004;199(6):775–784.
   PubMed Web of Science ®Google Scholar
• Sorensen MR, Adenoviral vaccination combined with CD40 stimulation and CTLA-4 blockage can lead to complete tumor regression in a murine melanoma model. Vaccine. 2010;28(41):6757–6764.
   Google Scholar
• Uno T, Eradication of established tumors in mice by a combination antibody-based therapy. Nat Med. 2006;12(6):693–698.
   PubMed Web of Science ®Google Scholar
• Westwood JA, Three agonist antibodies in combination with high-dose IL-2 eradicate orthotopic kidney cancer in mice. J Transl Med. 2010;8:42.
   PubMed Web of Science ®Google Scholar
• Christiansen AJ, Eradication of solid tumors using histone deacetylase inhibitors combined with immune-stimulating antibodies. Proc Natl Acad Sci U S A. 2011;108(10):4141–4146.
   PubMed Web of Science ®Google Scholar
• Liu C, Agonistic antibody to CD40 boosts the antitumor activity of adoptively transferred T cells in vivo. J Immunother. 2012;35(3):276–282.
   PubMed Web of Science ®Google Scholar
• Cho HI, A potent vaccination strategy that circumvents lymphodepletion for effective antitumor adoptive T-cell therapy. Cancer Res. 2012;72(8):1986–1995.
   PubMedGoogle Scholar
• Kerr JF, Wyllie AH, Currie AR. Apoptosis: a basic biological phenomenon with wide-ranging implications in tissue kinetics. Br J Cancer. 1972. 26(4):239–257.
   PubMed Web of Science ®Google Scholar
• Zitvogel L, Immunological aspects of cancer chemotherapy. Nat Rev Immunol. 2008;8(1):59–73.
   PubMed Web of Science ®Google Scholar
• Nowak AK, Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells. J Immunol. 2003;170(10):4905–4913.
   PubMed Web of Science ®Google Scholar
• Beatty GL, CD40 agonists alter tumor stroma and show efficacy against pancreatic carcinoma in mice and humans. Science. 2011;331(6024):1612–1616.
   PubMed Web of Science ®Google Scholar
• Buhtoiarov IN, Anti-tumour synergy of cytotoxic chemotherapy and anti-CD40 plus CpG-ODN immunotherapy through repolarization of tumour-associated macrophages. Immunology. 2011;132(2):226–239.
   PubMed Web of Science ®Google Scholar
• Johnson EE, Enhanced T-cell-independent antitumor effect of cyclophosphamide combined with anti-CD40 mAb and CpG in mice. J Immunother. 2011;34(1):76–84.
   Google Scholar
• Vonderheide RH, Phase I study of recombinant human CD40 ligand in cancer patients. J Clin Oncol. 2001;19(13):3280–3287.
   PubMed Web of Science ®Google Scholar
• Kalbasi A, Prevention of interleukin-2 withdrawal-induced apoptosis in lymphocytes retrovirally cotransduced with genes encoding an antitumor T-cell receptor and an antiapoptotic protein. J Immunother. 2010;33(7):672–683.
   PubMed Web of Science ®Google Scholar
• Drabick JJ, Schell TD. Poking CD40 for cancer therapy, another example of the Goldilocks effect. Cancer Biol Ther. 2010;10(10):994–996.
   PubMed Web of Science ®Google Scholar
• Forero-Torres NLB, A Phase 1b clinical trial of dacetuzumab in combination with rituximab and gemcitabine: multiple responses observed in patients with relapsed diffuse large B-cell lymphoma. In ASH Annual Meeting Abstracts. 2009. Blood. Conference abstract; Paper # 586.
   Google Scholar
• Burington B, CD40 pathway activation status predicts response to CD40 therapy in diffuse large B cell lymphoma. Sci Transl Med. 2011. 3(74):74ra22.
   PubMed Web of Science ®Google Scholar
• Cella M., Maturation, activation, and protection of dendritic cells induced by double-stranded RNA. J Exp Med. 1999;189(5):821–829.
   PubMed Web of Science ®Google Scholar
• Robinson RA, A phase I-II trial of multiple-dose polyriboinosic-polyribocytidylic acid in patieonts with leukemia or solid tumors. J Natl Cancer Inst. 1976;57(3):599–602.
   PubMedGoogle Scholar
• Nicodemus CF, Toll-like receptor-3 as a target to enhance bioactivity of cancer immunotherapy. Am J Obstet Gynecol. 2010;202(6):608 e1–e8.
   Google Scholar
• Krieg AM. Toll-like receptor 9 (TLR9) agonists in the treatment of cancer. Oncogene. 2008;27(2):161–167.
   PubMed Web of Science ®Google Scholar
• Jahrsdorfer B, Weiner GJ. CpG oligodeoxynucleotides as immunotherapy in cancer. Update Cancer Ther. 2008;3(1):27–32.
   PubMedGoogle Scholar
• Hennessy EJ, Parker AE, O'Neill LA. Targeting Toll-like receptors: emerging therapeutics? Nat Rev Drug Discov. 2010;9(4):293–307.
   PubMed Web of Science ®Google Scholar
• Singh SK, Design of neo-glycoconjugates that target the mannose receptor and enhance TLR-independent cross-presentation and Th1 polarization. Eur J Immunol. 2011;41(4):916–925.
   Google Scholar
• Ghosh M, CD13 regulates dendritic cell cross-presentation and T cell responses by inhibiting receptor-mediated antigen uptake. J Immunol. 2012.
   Google Scholar
• Hermans IF, NKT cells enhance CD4+ and CD8+ T cell responses to soluble antigen in vivo through direct interaction with dendritic cells. J Immunol. 2003;171(10):5140–5147.
   PubMed Web of Science ®Google Scholar
• Kitamura H., The natural killer T (NKT) cell ligand alpha-galactosylceramide demonstrates its immunopotentiating effect by inducing interleukin (IL)-12 production by dendritic cells and IL-12 receptor expression on NKT cells. J Exp Med. 1999;189(7):1121–1128.
   PubMed Web of Science ®Google Scholar
• Castellino F, Chemokines enhance immunity by guiding naive CD8+ T cells to sites of CD4+ T cell-dendritic cell interaction. Nature. 2006;440(7086):890–895.
   PubMed Web of Science ®Google Scholar
• Semmling V, Alternative cross-priming through CCL17-CCR4-mediated attraction of CTLs toward NKT cell-licensed DCs. Nat Immunol. 2010;11(4):313–320.
   PubMed Web of Science ®Google Scholar
• Dominguez AL, Lustgarten J. Targeting the tumor microenvironment with anti-neu/anti-CD40 conjugated nanoparticles for the induction of antitumor immune responses. Vaccine. 2010;28(5):1383–1390.
   PubMed Web of Science ®Google Scholar
• Li F, Ravetch JV. Inhibitory Fcgamma receptor engagement drives adjuvant and anti-tumor activities of agonistic CD40 antibodies. Science. 2011;333(6045):1030–1034.
   PubMed Web of Science ®Google Scholar
• White AL, Interaction with FcgammaRIIB is critical for the agonistic activity of anti-CD40 monoclonal antibody. J Immunol. 2011;187(4):1754–1763.
   PubMed Web of Science ®Google Scholar